ACC 25: Biocardia’s CardiAMP trial fails but cell therapy potential remains

At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results were reported in a late-breaker trials session on Biocardia’s Phase III CardiAMP autologous cell therapy trial for the treatment of heart failure with reduced ejection fraction (HFrEF) patients.